Dr Kozo Kataoka speaks to ecancer about the ctDNA status and adjuvant chemotherapy after resection of colorectal liver metastases. The study found that the role

Dr Wungki Park speaks to ecancer about the phase II GLEAM study, which evaluated zolbetuximab plus gemcitabine and nab-paclitaxel in patients with claudin 18 is

Dr Josep Tabernero speaks to ecancer about the final analysis of the phase III KRYSTAL-10 trial evaluating adagrasib plus cetuximab as second-line treatment for

Dr Michele Milella speaks to ecancer about an open-label, multi-centre, randomised study of TaRgeted intratumoural placement of phosphorous-32 microparticles ad

Dr Nilo Azad presents early phase 1 results of a novel dual RAS inhibition strategy using zoldonrasib and daraxonrasib in patients with heavily pretreated metas

Prof Martin Schrappe speaks to ecancer about a randomized trial that evaluated whether blinatumomab could safely replace highly intensive chemotherapy in childr

Prof Marek Trněný speaks to ecancer about the phase 2 CHEPA study that evaluated the addition of etoposide to brentuximab vedotin plus CHP (CHEP) in prev

Prof Umberto Vitolo speaks to ecancer about the phase 3 frontMIND trial. This trial evaluated the addition of tafasitamab and lenalidomide to standard R-CHOP

Prof Umberto Vitolo speaks to ecancer about the updated results from the phase 2 EPCORE DLBCL-3 trial evaluating fixed-duration epcoritamab monotherapy, a CD3&t

Prof Anthony Moorman speaks to ecancer about his study that evaluated outcomes in children and young people with chemotherapy-intolerant or resistant disease to

Prof Carsten Niemann speaks to ecancer about the first prospective, multicenter validation of the Chronic Lymphocytic Leukemia Treatment-Infection Model (CLL-TI

Dr Frederick Chen speaks to ecancer about real world evidence from the UK Adult ITP Registry evaluating the thrombopoietin receptor agonist romiplostim in acute

Prof David Kuter speaks to ecancer about his poster presentation that reports findings from a cross-sectional observational study evaluating fatigue in adults w

Prof Claire Harrison speaks to ecancer about results from the phase 3 SENTRY trial evaluating selinexor, an XPO1 nuclear export inhibitor, in combination with r

Dr Matthew Davids speaks to ecancer about results from the phase 3 BRUIN CLL 322 trial evaluating fixed-duration pirtobrutinib, a noncovalent BTK inhibitor, in

Prof Fabio Efficace speaks to ecancer about patient reported outcomes from the phase 3 APOLLO trial evaluating arsenic trioxide in combination with all trans re

Dr Johannes Schetelig speaks to ecancer about results from a large randomised controlled phase 3 trial comparing anti T lymphocyte globulin and post transplant

Prof Elias Jabbour speaks to ecancer about a phase 1/2 study that evaluated a subcutaneous formulation of blinatumomab in adults with heavily pretreated relapse

Prof Ashutosh Wechalekar speaks to ecancer about results from the phase 3 CARES trials evaluating anselamimab, a monoclonal antibody designed to promote clearan

Dr Ying Huang speaks to ecancer about the first-in-human trial of LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy for patients with relapsed or refrac

Dr Chiara Sartor speaks to ecancer about results from the phase 2 GIMEMA AML2521 trial evaluating venetoclax plus azacitidine as a molecular relapse interventio

Prof Christopher Fox speaks to ecancer about results from the phase 3 EPCORE DLBCL-1 trial comparing epcoritamab monotherapy with investigator’s choice ch

Dr Benoit Tessoulin speaks to ecancer about a subgroup analysis from the phase 3 EPCORE FL-1 trial evaluating epcoritamab in combination with rituximab and lena

Prof Martin Wermke speaks to ecancer about results from the Phase Ia RevSTAR-123 study evaluating AVC-201-01, a switchable allogeneic CD123-targeted CAR-T

Dr Hanny Al-Samkari speaks to ecancer about the evolving treatment landscape in immune thrombocytopenia, highlighting emerging therapeutic targets that may resh

Dr Peter Voorhees speaks to ecancer about results from the phase 3 MonumenTAL 3 trial evaluating talquetamab, a GPRC5D targeting bispecific antibody, in combina

Dr Nancy Y. Lee talks to ecancer at ASCO 2026 about long-term follow-up data on FMISO PET-guided radiation dose de-escalation in patients with HPV-associated or

Dr Giannis Mountzios speaks to ecancer about the DeLLphi-304 study. This analysis highlights the intracranial efficacy of tarlatamab, a bispecific T-cell eng

Dr Elizabeth McDonald talks to ecancer at ASCO 2026 about findings from a large observational study evaluating the association between GLP-1 receptor agonist us

Dr Marlana Orloff speaks to ecancer about the phase 2/3 OptimUM-02 trial. This trial evaluates darovasertib (PKC inhibitor) combined with crizotinib (MET inh

Dr Gentry talks to ecancer at ASCO 2026 about retrospective data evaluating aspirin use in patients with endometrial cancer. The analysis found that aspirin use

Dr Lucia Nappi speaks to ecancer at ASCO 2026 about findings from the S1823/GCC.1 study, a trial evaluating circulating miR371 as a biomarker for relapse in pat

Prof Tony Mok speaks to ecancer about the long-term follow-up from the phase 3 CROWN trial. It shows that lorlatinib continues to provide exceptional and durabl

At ASCO 2026, ecancer talks to Dr Jessica Paulus about real-world data evaluating GLP-1 receptor agonist use in patients with cancer treated within a large US o

At ASCO 2026, Dr Paul Richardson talks to ecancer about results from the phase III SUCCESSOR-2 study evaluating mezigdomide plus carfilzomib and dexamethasone i

Dr Nandini Menon speaks to ecancer about a phase 3 randomised trial evaluates the addition of low-dose pembrolizumab to platinum-doublet chemotherapy in patient

Dr Karen Mustian speaks to ecancer about a phase III randomised trial explores the impact of a structured yoga program (YOCAS) on mood disturbance, fatigue, and

Dr Brian Wolpin talks to ecancer at ASCO 2026 about results from the phase 3 RASolute 302 trial evaluating daraxonrasib as second-line treatment for metastatic

Dr Kibel talks to ecancer at ASCO 2026 about data from the PROTEUS trial. The phase 3 PROTEUS trial evaluated perioperative apalutamide (APA) plus androgen d

Dr Mark Dickson talks to ecancer at ASCO 2026 about findings from a phase III trial evaluating abemaciclib in patients with recurrent dedifferentiated liposarco

Dr Jonathan Goldman talks to ecancer at ASCO 2026 about findings from the phase III LIBRETTO-432 trial evaluating adjuvant selpercatinib in patients with early-